###### Strengths and limitations of this study

-   This is the first systematic review and meta-analysis to provide a comprehensive estimate of the prevalence of depression or depressive symptoms among outpatients considering different clinical specialties.

-   The information provided by this study highlights the importance of developing effective management strategies for the early identification and treatment of depression among outpatients in clinical practice.

-   The substantial heterogeneity between included studies was not fully explained by the variables examined.

-   The paucity of longitudinal data may decrease the generalisability of the study outcomes.

Introduction {#s1}
============

Depression is the leading cause of disability and is a major contributor to the disease burden worldwide. The global prevalence of depression and depressive symptoms has been increasing in recent decades.[@R1] The lifetime prevalence of depression ranges from 20% to 25% in women and 7% to 12% in men.[@R2] Depression is a significant determinant of quality of life and survival, accounting for approximately 50% of psychiatric consultations and 12% of all hospital admissions.[@R3] Notably, the prevalence of depression or depressive symptoms is higher in patients than in the general public.[@R3] The underlying reasons include the illness itself and the heavy medical cost, unsatisfactory medical care service and poor doctor--patient relationship.[@R7] Several informative systematic reviews on specific groups of outpatients have been published. For example, Mitchell *et al* estimated that the prevalence of depression in oncology and haematology patients was 9.6%--16.5%.[@R5] Depression is a significant comorbidity of chronic medical disorders. The prevalence of depression in chronic medical conditions is as follows: asthma (27%),[@R9] atopic dermatitis (5%),[@R10] chronic obstructive pulmonary disease (24.6%),[@R11] gouty arthritis (20%),[@R12] rheumatoid arthritis (15%),[@R13] systemic lupus erythematosus (22%)[@R12] and stroke (30%).[@R14] Ismail *et al* conducted a meta-analysis of 57 studies and showed that the overall pooled prevalence of depression in patients with mild cognitive impairment was 32%.[@R4] Estimates of the prevalence of depression and depressive symptoms vary substantially between published studies, particularly with respect to specialty, patient age and residence. The inconsistency across different studies may originate from the lack of a clear definition or gold standard for the diagnosis of depression and depressive symptoms. Many previous studies have focused on depression and depressive symptoms in inpatient settings; however, mental disorders in outpatients are largely underestimated.[@R6] Depression in outpatients is associated with high indirect costs due to loss of productivity and unemployment.[@R8] The combination of chronic medical illnesses and depression will lead to significant economic burden.[@R8] Additionally, it is important for healthcare workers to identify mental status changes in outpatients, as mental states may affect the doctor--patient relationship and can influence patient satisfaction with medical care.[@R16] To the best of our knowledge, no previous studies have quantitatively analysed a robust dataset with information on depression and depressive symptoms among outpatients in different clinical departments. Therefore, conducting a systematic review and meta-analysis of the depression prevalence detected during doctor visits is essential to informing efforts to prevent and treat depression and depressive symptoms among outpatients. In this study, we aimed to quantitatively summarise the prevalence of depression and depressive symptoms in different clinical departments.

Methods {#s2}
=======

Study selection {#s2a}
---------------

Relevant studies published before January 2016 that described the prevalence of depression or depressive symptoms in patients from different specialties were identified using the PubMed and PsycINFO, EMBASE and Cochrane Library databases (by WJH and WXH); the selected articles were then screened by title, abstract and reference lists in collaboration with study investigators using the approach recommended by the Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines.[@R17] Potentially relevant papers were first identified through title and abstract searches. The full text of the retrieved articles was then assessed. The search strategy involved applying the 'explode' command to search the MeSH terms 'depression' and 'depressive symptoms' and 'outpatient\*'; the combined terms were related to 'prevalence', 'cross-sectional studies' or 'controlled studies' and 'different specialties', such as 'internal medicine', 'surgical specialties' and 'paediatrics', with language restrictions (articles published in English only). More search strategy details can be found in online [supplementary method 1](#SP1){ref-type="supplementary-material"}. The study inclusion criteria were the following: (1) articles that included patients diagnosed with a specific disease other than psychiatric disorders; (2) articles in peer-reviewed journals that involved only patients with a current degree of clinically relevant depression sufficient to warrant clinical intervention, regardless of the depression severity (mild, moderate or severe)[@R18]; (3) studies in which depression was confirmed by validated self-report instruments or diagnostic structured interviews[@R19]; (4) articles with study populations who were recruited from outpatient clinics only. The exclusion criteria were as follows: (1) studies that failed to report the specific prevalence of depression, (2) studies on patients whose depression predated any other physical disorder and (3) studies on patients diagnosed with more than one psychiatric disorder (in addition to depression).
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Data extraction and quality assessment {#s2b}
--------------------------------------

Data extraction was a multistep process based on the eligibility criteria. The following information was extracted from each study independently by two investigators (JHW and XHW) independently using a standardised form: study design, research year, country, specialty category, disease, sample size, diagnostic or screening method used and reported prevalence of depression and depressive disorders. A modified version of the Newcastle-Ottawa Scale was used to evaluate the quality of non-randomised studies.[@R20] Studies were identified as having a low risk of bias (≥3 points) or a high risk of bias (\<3 points). The effect of individual studies on the overall prevalence estimate was explored by serially excluding each study in a sensitivity analysis. Additionally, two reviewers (JHW and XHW) cross-checked the reference lists of all selected articles to identify other relevant studies. All discrepancies were resolved by discussion and consensus.

Statistical analysis {#s2c}
--------------------

As considerable heterogeneity was expected because of the multiple sources of variance, a random-effects model was used to estimate the pooled prevalence of depressive symptoms.[@R21] Random-effect model attempted to generalise findings beyond the included studies by assuming that the selected studies are random samples from a larger population.[@R22] The observed heterogeneity in the depression prevalence among outpatients may be attributed to differences in the assessment methods used to detect depression, the variation in thresholds in the different validated depression measurements, the specialties examined, the study countries, study year, patient ages and other factors. Thus, subgroup analyses were performed. Binomial proportion CIs for individual studies were calculated using the Clopper-Pearson method, which allows for asymmetry.[@R23] Between-study heterogeneity was evaluated using standard χ^2^ tests and the I^2^ statistic.[@R21] I^2^ statistics were calculated to describe the percentages of total variation across studies caused by heterogeneity. A 0% value indicated no heterogeneity, and higher values represented an increase in heterogeneity. Generally, heterogeneity is categorised as 25% (low), 50% (moderate) and 75% (high).[@R24] The results of the analysis were compared in terms of descriptive characteristics (age, specialty, study year, diagnostic method and country) using subgroup analysis and meta-regression. For models with considerable heterogeneity, a meta-regression was performed to identify the moderators that might contribute to the heterogeneity of the effect sizes.[@R25] Publication bias of the studies was examined using funnel plots and Egger's test.[@R26] All analyses were performed using R version 3.3.1 (R Foundation for Statistical Computing, Vienna, Austria) and Review Manager version 5.3 (The Cochrane Collaboration, 2015, the Nordic Cochrane Centre, Copenhagen, Denmark). Statistical tests were two-sided with a significance threshold of p\<0.05. This study is registered with PROSPERO, number CRD42017054738.

Patient involvement {#s2d}
-------------------

No patients eligible for screening were involved in the design and conduct of the study or involved in defining the research question or outcome measures. We have no intentions to disseminate our results to patients eligible for screening.

Results {#s3}
=======

Screening the titles and abstracts resulted in 3165 articles, 110 of which were duplicates, and only 207 articles were retrieved for a detailed, full-text assessment. Of these, 83 studies fulfilled the inclusion criteria; 101 studies did not meet the eligible population criteria, 8 failed to present point prevalence data and 15 used improper outcome measures and were excluded.

Eighty-three cross-sectional studies involving a total of 41 344 individuals were included in the study ([figure 1](#F1){ref-type="fig"}). Study participants were recruited from 11 departments: 22 studies recruited patients from internal medicine clinics, 12 from primary care, 10 from neurology, 8 from dermatology, 7 from obstetrics/gynaecology, 6 from ophthalmology, 6 from oncology, 5 from infectious diseases, 4 from surgery, 3 from paediatrics and 3 from otolaryngology departments. Most (29) of the studies were conducted in Europe; 21 were performed in Asia, 19 in North America, 4 in South America, 4 in Oceania, 3 in the Middle East and 1 in Africa. Seventeen studies used the Beck Depression Inventory (BDI) to assess depression; 10, the Hospital Anxiety and Depression Scale (HADS); 7, the Patient Health Questionnaire; 6, the Hamilton Depression Scale, also called the Hamilton Depression Rating Scale; and 43, other methods. The full study characteristics are summarised in [table 1](#T1){ref-type="table"}. The overall prevalence estimates of depression or depressive symptoms reported by the 83 studies yielded a summary prevalence of 27.0% (10 943/41 344 individuals, 95% CI 24.0% to 29.0%), with significant between-study heterogeneity (p\<0.0001, τ*^2^*=0.3742, I^2^=96.7%). Subgroup analyses by age, clinical department, study year, country and diagnosis method were conducted to explore the potential heterogeneity between studies. Of the 83 studies, the highest depression/depressive symptom prevalence estimates occurred in studies of outpatients from otolaryngology clinics (357/796, 53.0%, 95% CI 39.0% to 66.0%, I^2^=79.8%), followed by dermatology clinics (520/1558, 39.0%, 95% CI 24.0% to 56.0%, I^2^=96.9%) and neurology clinics (3328/9280, 35.0%, 95% CI 30.0% to 40.0%, I^2^=94.4%). The prevalences of depression among outpatients from other specialties are summarised in [figure 2](#F2){ref-type="fig"}. Subgroup analysis was conducted to compare studies in developed countries versus in developing countries (7788/29 208, 24.0%, 95% CI 21.0% to 27.0%, I^2^=97.0%, p\<0.0001 vs 3188/12 050, 33.0%, 95% CI 28.0% to 38.0%, I^2^=96.8%, p\<0.0001). The prevalence of depression/depressive symptoms in outpatients decreased from 36.0% to 24.0% from 1990 to 2010, followed by a slight increase from 2011 to 2016. Outpatients who were younger than 30 years old showed the lowest depression prevalence, at 20.0% (170/797, 95% CI 14.0% to 28.0%, I^2^=81.6%, p=0.0010), whereas the highest depression prevalence was reported in outpatients older than 80 years at 34.0% (397/2128, 95% CI 15.0% to 69.0%, I^2^=96.8%, p\<0.0001). The prevalences reported in studies stratified by year are presented in [figure 3](#F3){ref-type="fig"}. Eight studies with healthy controls were included in a subgroup. There was a significantly higher prevalence of depression and depressive symptoms in outpatients than in healthy controls (OR 3.16, 95% CI 2.66 to 3.76, I^2^=72.0%, χ*^2^*=25.33) ([figure 4](#F4){ref-type="fig"}).
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###### 

Selected characteristics of the 83 studies included in this systematic review and meta-analysis

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                 Specialty            Disease category                            Country            Mean age\       Time point\                     Study\                        Diagnostic method      Depression prevalence %\   NOS
                                                                                                                            (SD)            (year, month)                   design                                               (cases/participants)       
  ------------------------------------- -------------------- ------------------------------------------- ------------------ --------------- ------------------------------- ----------------------------- ---------------------- -------------------------- -----
  Rohani *et al*[@R53]                  Internal medicine    Cardiology                                  Iran               50.4 (NR)       April 2010--November 2010       Descriptive cross-sectional   HADS                   31.0% (78/250)             5

  Bokemeyer *et al*[@R54]               Internal medicine    Gastroenterology                            Germany            43 (NR)         March 2006--July 2007           Descriptive cross-sectional   SF-36                  14.9% (154/1032)           4

  Tedeschini *et al*[@R55]              Internal medicine    Rheumatology                                Italy              53.7 (12.1)     February 2005--July 2007        Descriptive cross-sectional   BDI                    46.2% (36/78)              4

  Yohannes *et al*[@R56]                Internal medicine    Pulmonary disease                           UK                 73 (NR)         NR                              Descriptive cross-sectional   GMS, MADRS, \          42.0% (57/137)             4
                                                                                                                                                                                                          BASDEC                                            

  Yohannes *et al*[@R57]                Internal medicine    Pulmonary disease                           UK                 78 (5)          NR                              Controlled cross-sectional    BASDEC                 46.0% (44/96)              3

  Noh *et al*[@R58]                     Internal medicine    Endocrinology                               Korea              52.7 (12.2)     March 2003--October 2003        Controlled cross-sectional    BDI                    32.4% (66/204)             5

  Janke *et al*[@R59]                   Internal medicine    Gastroenterology                            Germany            43.2 (11.0)     January 1997--December 2000     Descriptive cross-sectional   HADS                   10.2% (43/429)             4

  Zhang *et al*[@R60]                   Internal medicine    Internal medicine                           China              44.4 (16.5)     July 2011--June 2012            Descriptive cross-sectional   PHQ-9                  9.2% (37/404)              4

  He *et al*\*[@R61]                    Internal medicine    Cardiology                                  China              40.1 (17.3)     April 2007--July 2007           Descriptive cross-sectional   HADS, GHQ-15           26.7% (140/524)            4

  He *et al*\*[@R61]                    Internal medicine    Gastroenterology                            China              40.1 (17.3)     April 2007--July 2007           Descriptive cross-sectional   HADS, GHQ-15           26.9% (181/674)            4

  Pontone *et al*[@R62]                 Internal medicine    Gastroenterology                            Italy              53.3 (17)       May 2009--October 2010          Descriptive cross-sectional   BDI                    17.2% (22/130)             3

  Urrutia *et al*[@R63]                 Internal medicine    Pulmonary disease                           Spain              44.25 (16.77)   December 2006--December 2007    Descriptive cross-sectional   HADS                   1.7% (6/354)               3

  Zhang *et al*[@R64]                   Internal medicine    Endocrinology                               China              55.1 (9.5)      July 2010--July 2011            Descriptive cross-sectional   PHQ-9                  18.3% (107/586)            4

  Birket-Smith *et al*[@R65]            Internal medicine    Cardiology                                  Denmark            67.4 (13.63)    2011                            Descriptive cross-sectional   DSM-III-R, HAMD        19.7% (17/86)              4

  Hajduk *et al*[@R66]                  Internal medicine    Rheumatology                                Poland             43.79 (11.66)   2009--2013                      Descriptive cross-sectional   HADS-M                 35.8% (19/53)              4

  Qin *et al*[@R67]                     Internal medicine    Internal medicine                           China              48.1 (17.7)     November 2004--January 2006     Descriptive cross-sectional   GHQ SI                 34.6% (495/1428)           4

  Inagaki *et al*[@R68]                 Internal medicine    Internal medicine                           Japan              75 (NR)         July 2010                       Descriptive cross-sectional   PHQ-9                  9.0% (36/396)              5

  Schaefert *et al*[@R69]               Internal medicine    Internal medicine                           Germany            43.2 (14.2)     August 2009--October 2009       Descriptive cross-sectional   PHQ-15, HADS           4.6% (13/281)              3

  Addolorato *et al*[@R70]              Internal medicine    Gastroenterology                            Italy              43.9 (15.9)     1997--2015                      Descriptive cross-sectional   ZUNG SDS               27.0% (442/1641)           4

  Pouwer *et al*[@R71]                  Internal medicine    Endocrinology                               Netherlands        43(14)          NR                              Descriptive cross-sectional   CESD                   33.6% (243/724)            5

  Su *et al*[@R72]                      Internal medicine    Nephrology                                  China              59.8 (11.9)     NR                              Descriptive cross-sectional   BDI                    40.3% (129/320)            5

  Xiong *et al*[@R73]                   Internal medicine    Internal medicine                           China              44.9 (16.4)     February 2011--October 2012     Descriptive cross-sectional   PHQ-9, MINI            38.3% (188/491)            5

  Tsunoda *et al*[@R74]                 Oncology             Colorectal cancer                           Japan              69 (10.5)       1994--2005                      Descriptive cross-sectional   HADS                   36.7% (47/128)             4

  Polidoro Lima and Osório[@R75]        Oncology             Oncology                                    Brazil             50.3 (13.9)     NR                              Descriptive cross-sectional   PHQ-4                  18.6% (257/1385)           4

  Alcalar, N et al[@R76]                Oncology             Breast cancer                               Turkey             48.32 (8.46)    September 2008--April 2009      Descriptive cross-sectional   BDI                    30.9% (34/110)             3

  Jehn *et al*[@R77]                    Oncology             Metastatic breast cancer                    Germany            59.9 (10.2)     NR                              Descriptive cross-sectional   HADS                   31.4% (22/70)              4

  Qiu *et al*[@R78]                     Oncology             Postsurgery breast cancer                   China              52.02 (4.55)    January 2008--March 2009        Descriptive cross-sectional   BDI, HAMD, \           18.8% (95/505)             4
                                                                                                                                                                                                          MINI                                              

  Reuter *et al*[@R6]                   Oncology             Gynaecological and  breast cancer           Germany            54 (19.81)      May 1998--June 2000             Descriptive cross-sectional   HADS                   15.2% (10/66)              3

  Diniz *et al*[@R79]                   Surgery              Renal colic                                 Brazil             43.8 (14.4)     June 2003--October 2003         Controlled cross-sectional    BDI                    59.4% (19/32)              4

  Hung *et al*[@R80]                    Surgery              Orthopaedics                                China              40.7 (11.4)     NR                              Descriptive cross-sectional   HADS                   21.8% (49/225)             4

  Jung *et al*[@R81]                    Surgery              Chronic peritoneal dialysis                 Korea              54.2 (10.24)    July 2009--October 2009         Descriptive cross-sectional   BDI                    35.7% (20/56)              4

  Weisbord *et al*[@R82]                Surgery              Chronic haemodialysis                       USA                64 (NR)         2009--2011                      Descriptive cross-sectional   PHQ-9                  25.5% (73/286)             4

  Bixo *et al*[@R83]                    OG                   Gynaecology                                 Sweden             43.8 (14.3)     November 1998--December 1998    Descriptive cross-sectional   PRIME-MD               27.2% (208/766)            4

  Gaillard *et al*[@R84]                OG                   Postpartum                                  France             31 (NR)         November 2007--November 2009    Descriptive cross-sectional   EPDS                   16.7% (44/264)             4

  Lorencatto *et al*\*[@R85]            OG                   Endometriosis with chronic pelvic pain      Brazil             35.3 (6.4)      NR                              Descriptive cross-sectional   BDI                    86.0% (43/50)              4

  Lorencatto *et al*\*[@R85]            OG                   Endometriosis without chronic pelvic pain   Brazil             32.8 (7.1)      NR                              Descriptive cross-sectional   BDI                    38.0% (19/50)              4

  Poleshuck *et al*[@R86]               OG                   Gynaecology                                 USA                32.1 (NR)       March 2004--December 2004       Descriptive cross-sectional   BDI                    21.8% (51/234)             4

  He *et al*\*[@R61]                    OG                   Gynaecology                                 China              40.1 (17.3)     April 2007--July 2007           Descriptive cross-sectional   HADS, GHQ-15           18.6% (103/554)            4

  Wang *et al*[@R87]                    OG                   Menopause                                   China              NR              2004                            Descriptive cross-sectional   HADS                   11.1% (34/306)             2

  Wojnar *et al*[@R88]                  OG                   Gynaecology                                 Poland             49.85 (3.09)    May 2001--October 2001          Descriptive cross-sectional   BDI, ICD-10            19.5% (442/2262)           4

  Stewart *et al*[@R89]                 Paediatrics          T1DM                                        USA                13.54 (1.56)    December 2001--May 2003         Descriptive cross-sectional   CESD                   30.0% (62/205)             3

  Zdunczyk *et al*[@R90]                Paediatrics          T1DM                                        Poland             14.2 (2.0)      October 2011--November 2012     Descriptive cross-sectional   CDI                    19.4% (72/372)             4

  Winter *et al*[@R91]                  Paediatrics          Paediatrics                                 USA                13.89 (1.58)    NR                              Descriptive cross-sectional   BDI-PC                 11.0% (11/100)             3

  Carson *et al*[@R52]                  Neurology            Neurology                                   UK                 43.4 (NR)       2003                            Analytical Cohort-study       HADS, PRIME-MD         39.7% (119/300)            4

  Carson *et al*[@R92]                  Neurology            Neurology                                   UK                 43 (16.2)       November 1997--March 1998       Descriptive cross-sectional   HADS, PRIME-MD         33.3% (100/300)            4

  de Oliveira *et al*[@R93]             Neurology            Temporal lobe epilepsy                      Brazil             40.7 (10.1)     NR                              Descriptive cross-sectional   HAMD                   35.4% (34/96)              4

  Dickstein *et al*\*[@R94]             Neurology            Epilepsy                                    USA                48 (17)         October 2007--August 2013       Descriptive cross-sectional   PHQ-9                  36.3% (1003/2763)          4

  Dickstein *et al*\*[@R94]             Neurology            Multiple sclerosis                          USA                51 (12)         October 2007--August 2013       Descriptive cross-sectional   PHQ-9                  39.4% (1507/3823)          4

  He *et al*\*[@R61]                    Neurology            Neurology                                   China              40.1 (17.3)     April 2007--July 2007           Descriptive cross-sectional   HADS, GHQ-15           30.7% (216/704)            4

  Mao *et al*\*[@R95]                   Neurology            Parkinson's disease                         China              NR              August 2010--June 2011          Descriptive cross-sectional   HAMD                   56.2% (68/121)             2

  Mao *et al*\*[@R95]                   Neurology            Essential tremor                            China              NR              July 2009--June 2010            Descriptive cross-sectional   HAMD                   53.2% (33/62)              2

  Mitsikostas and Thomas[@R96]          Neurology            Headache                                    Greece             41 (7)          2007                            Controlled cross-sectional    HAMD                   3.4% (16/470)              4

  Vogel *et al*[@R97]                   Neurology            Systemic lupus erythematosus                Denmark            41.8 (9.6)      2010                            Descriptive cross-sectional   MDI                    22.8% (13/57)              4

  Williams *et al*[@R98]                Neurology            Neurology                                   USA                51.1 (21)       January 2001--August 2001       Descriptive cross-sectional   PHQ-9                  33.3% (161/483)            5

  Worku *et al*[@R99]                   Neurology            Parkinson's disease                         USA                57.10 (10.84)   June 2013--November 2013        Descriptive cross-sectional   QIDS-C16               57.4% (58/101)             4

  Attah Johnson and Mostaghimi[@R100]   Dermatology          Neurodermatitis                             Papua New Guinea   NR              1992                            Descriptive cross-sectional   SRQ                    50.7% (67/132)             4

  Balieva *et al*[@R101]                Dermatology          Dermatology                                 Norway             50.1 (17.7)     November 2011--February 2013    Controlled cross-sectional    HDRS                   13.3% (77/577)             5

  Hon *et al*[@R102]                    Dermatology          Atopic eczema                               China              16.0 (NR)       May 2012--October 2012          Controlled cross-sectional    DASS-42, BDI           20.8% (25/120)             4

  Mattoo *et al*\*[@R103]               Dermatology          Vitiligo                                    India              30.11 (12.49)   March 1998--September 1999      Controlled cross-sectional    GHQ, CPRS              22.1% (25/113)             4

  Mattoo *et al*\*[@R103]               Dermatology          Psoriasis                                   India              40.91 (14.26)   March 1998--September 1999      Controlled cross-sectional    GHQ, CPRS              29.1% (30/103)             4

  Rasoulian *et al*[@R104]              Dermatology          Dermatology                                 Iran               NR              September 2007--December 2007   Controlled cross-sectional    HADS                   70.1% (101/144)            4

  Roca *et al*[@R105]                   Dermatology          Scleroderma                                 USA                NR              NR                              Descriptive cross-sectional   BDI                    64.8% (35/54)              3

  Singh *et al*[@R106]                  Dermatology          Psoriasis                                   India              NR              January 2013--November 2013     Descriptive cross-sectional   PHQ-9                  39.4% (41/104)             3

  Tsintsadze *et al*[@R107]             Dermatology          Skin diseases                               Ukraine            NR              NR                              Descriptive cross-sectional   HDRS                   56.2% (119/211)            5

  Daaleman *et al*[@R108]               Primary care         NR                                          USA                57 (NR)         NR                              Descriptive cross-sectional   ZUNG                   2.9% (15/509)              4

  Drayer *et al*[@R109]                 Primary care         Haemodialysis                               USA                61.6 (12.6)     July 2002--June 2003            Descriptive cross-sectional   PRIME-MD,\             27.4% (17/62)              4
                                                                                                                                                                                                          PHQ-9                                             

  Hankin *et al*[@R110]                 Primary care         NR                                          USA                NR              June 1993--May 1995             Descriptive cross-sectional   CESD                   31.3% (676/2160)           5

  Hollifield *et al*[@R111]             Primary care         NR                                          Japan              50.5 (19.3)     NR                              Descriptive cross-sectional   N.I.M.H.D              23.0% (29/126)             2

  Ishikawa *et al*[@R112]               Primary care         NR                                          USA                40.2 (13.4)     January 2012--June 2012         Descriptive cross-sectional   ICPC-2                 2.4% (29/1194)             4

  Michalski *et al*[@R113]              Primary care         NR                                          Japan              NR              NR                              Descriptive cross-sectional   DSM-III-R, BDI         5.7% (40/698)              4

  Okumura *et al*[@R114]                Primary care         Headache                                    France             45 (NR)         April 2005--March 2009          Descriptive cross-sectional   DSM-IV                 8.4% (35/418)              5

  Rondet *et al*[@R115]                 Primary care         NR                                          USA                NR              September 2010--December 2010   Descriptive cross-sectional   Structure interview    56.7% (142/250)            4

  Steer *et al*[@R116]                  Primary care         NR                                          USA                NR              NR                              Descriptive cross-sectional   BDI                    24.2% (29/120)             4

  Tamburrino *et al*[@R117]             Primary care         NR                                          USA                42.7 (NR)       1996--1998                      Descriptive cross-sectional   PRIME-MD PQ            27.3% (478/1752)           5

  Mancuso *et al*[@R118]                Primary care         Pulmonary disease                           UK                 41 (11)         NR                              Descriptive cross-sectional   GDS                    45.2% (104/230)            5

  Lee *et al*[@R119]                    Ophthalmology        Eye disease                                 USA                NR              January 2001--March 2011        Descriptive cross-sectional   Structured interview   20.0% (10/50)              4

  Rovner *et al*[@R120]                 Ophthalmology        ARMD                                        USA                81.2 (5.8)      NR                              Descriptive cross-sectional   HDRS                   23.7% (49/206)             5

  Evans *et al*[@R121]                  Ophthalmology        Eye disease                                 UK                 81.2 (4.8)      NR                              Controlled cross-sectional    GDS-15                 13.5% (235/1742)           4

  Brody *et al*[@R122]                  Ophthalmology        ARMD                                        USA                80.11 (6.21)    January 1998--September 1999    Descriptive cross-sectional   GDS, SI                32.5% (49/151)             4

  Mathew *et al*[@R123]                 Ophthalmology        ARMD                                        Australia          78.0 (7.7)      December 2001--July 2005        Controlled cross-sectional    GAD                    44.4% (64/145)             3

  Popescu *et al*[@R124]                Ophthalmology        ARMD, FCD, glaucoma                         Canada             80.5 (7.5)      September 2009--December 2011   Controlled cross-sectional    GDS-15                 24.8% (78/315)             4

  Goto *et al*[@R125]                   E.N.T.               Otolaryngology                              Japan              53.7 (18.9)     January 2006--December 2006     Descriptive cross-sectional   SDS                    54.4% (49/90)              4

  Asghari *et al*[@R126]                E.N.T.               OSAS                                        Iran               47.63 (11.73)   August 2008--December 2012      Descriptive cross-sectional   BDI                    41.3% (293/685)            4

  Lee *et al*[@R127]                    E.N.T.               Empty nose syndrome                         China              51.6 (NR)       2012--2014                      Analytical cohort-study       BDI                    71.4% (15/21)              4

  Olley *et al*[@R128]                  Infectious disease   HIV/AIDS                                    South Africa       NR              NR                              Descriptive cross-sectional   MINI                   34.9% (52/149)             4

  Kolaric *et al*[@R129]                Infectious disease   HIV/AIDS                                    Croatia            39 (NR)         March 2003--April 2003          Controlled cross-sectional    BDI                    20.0% (16/80)              3

  Chan *et al*[@R130]                   Infectious disease   HBV                                         China              47.2 (11.9)     October 2008--June 2009         Descriptive cross-sectional   GHQ                    17.4% (26/149)             4

  Wright *et al*[@R131]                 Infectious disease   HIV/AIDS                                    Australia          NR              July 2005--March 2006           Descriptive cross-sectional   CES-D                  36.4% (235/645)            4

  Judd *et al*[@R132]                   Infectious disease   HIV/AIDS                                    Australia          44.7 (9.1)      NR                              Descriptive cross-sectional   BDI                    34.8% (45/129)             3
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*Studies that extracted different data from the same research.

ARMD, age-related macular degeneration; BASDEC, Brief Assessment Schedule Depression Cards; BDI, Beck Depression Inventory; CES-D, Centre for Epidemiologic Studies Depression Scale; CIDI, Composite International Diagnostic Interview; CPRS, Comprehensive Psychopathological Rating Scale; DASS-42, Chinese versions of the Depression, Anxiety, Stress Scales; DSM, Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition); E.N.T., otorhinolaryngology department (ear, nose, throat); EPDS, Edinburgh Postnatal Depression Scale; FCD, Fuchs Corneal Dystrophy; GADS, Goldberg Anxiety and Depression Scale; GDS, Geriatric Depression Scale; GHQ, General Health Questionnaire; HADS, Hospital Anxiety and Depression Scale; HDRS, Hamilton Depression Rating Scale; ICPC-2, International Classification of Primary Care, Second Edition; MADRS, Montgomery-Asberg Depression Rating Scale; MDI, Major Depression Inventory; MINI, MINI International Neuropsychiatric Interview; N.I.M.H.D, N.I.M.H. Diagnostic Interview Schedule; NOS, Newcastle-Ottawa Score; NR, not reported; OG, obstetrics and gynaecology; OSAS, obstructive sleep apnea syndrome; PHQ-15, 15-item Patient Health Questionnaire; PHQ-9, 9-item Patient Health Questionnaire; PRIME-MD PQ, Primary Care Evaluation of Mental Disorders Patient Questionnaire; QIDS-C16, Quick Inventory of Depressive Symptomatology; SDS, Self-Rating Depression Scale; SF-36, Short F; SRQ, Self-Rating Questionnaire; T1DM, type 1 diabetes mellitus; WHO-5, World Health Organization-5 Well-Being Index.

Regarding the screening instruments used, higher prevalence estimates were found among studies that used BDI (1316/4702, 36.0%, 95% CI 29.0% to 44.0%, I^2^=94.8%) compared with those that used HADS (1003/2025, 22.0%, 95% CI 12.0% to 35.0%, I^2^=96.6%). A meta-regression analysis was conducted to evaluate the potential heterogeneity in combined subtypes to assess study year, country and specialty as sources of heterogeneity. In this analysis, country, study year and specialties represented a small amount of heterogeneity (p=0.0327, \<0.05). Funnel plots and tests indicated evidence of publication bias (Egger's test, p\<0.001, [figure 5](#F5){ref-type="fig"}). Sensitivity analyses, in which the meta-analysis was serially repeated after excluding each study, suggested that no individual study affected the overall prevalence estimate by more than 1% (online [supplementary table 1](#SP2){ref-type="supplementary-material"}).
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![Funnel plots to test the publication bias of the 8 studies that included control groups. Each point represents a separate study on the indicated association. The points were distributed asymmetrically, indicating the existence of publication bias.](bmjopen-2017-017173f05){#F5}

Discussion {#s4}
==========

We performed a systematic review and meta-analysis to best estimate the prevalence of depression and depressive symptoms in different clinical departments. Overall, the prevalence of depression or depressive symptoms among outpatients was 27.0%, ranging from 17.0% to 53.0% in different clinical departments. This study found that outpatients from otolaryngology clinics had the highest prevalence of depression (53.0%). Depression was found to be an important mediator for otolaryngologic conditions such as chronic tinnitus.[@R27] It was not surprising that dermatology ranked the second highest and 39.0% of outpatients from dermatology clinics suffered from depression. Atopic dermatitis was found to be associated with depression because the skin stigmata often causes embarrassment, low confidence and sadness.[@R10] Atopic dermatitis is one of the most common dermatological disorders and was found to be associated with negative impact on the quality of life of patients, families and caregivers.[@R29] There is psychoneuroimmunology connection between depression and medical illness.[@R31] The production of pro-inflammatory cytokine (eg, IL-6) was found to be higher in patients with atopic dermatitis[@R32] and IL-6 was found to be raised in patients with depression.[@R33] Raised IL-6 may cause depression in patient with atopic dermatitis. This study found that 35% of outpatients from neurology clinic suffered from depression. Genetic factors and autoantibodies play an important role in causing neuropsychiatric complications including depression.[@R34] Stroke is a common neurological disorder and causes significant health burden.[@R36] The burden of stroke causes depression in both stroke patients and their caregivers.[@R37] Novel rehabilitation intervention targeting at motor deficit was designed to improve functional status and quality of life of patients with stroke.[@R36] This intervention might offer hope and reduce prevalence of depression in patients with stroke. Our study confirmed previous findings of the higher prevalence of depression or depressive symptoms in outpatients than in the general public.[@R3] The prevalence of depression/depressive symptoms in outpatients slightly decreased from 1990 to 2010. This decrease may be due to the potentially improved recognition of the illness and increased awareness for seeking help among the general public. However, this explanation has yet to be confirmed with population-based research. Depression or depressive symptoms are often overlooked during daily medical care by busy professionals without specific training in mental health, and our findings suggests that specialists should focus on patients' physical problems and their mental problems. We should enhance the awareness of mental disorders during medical works and strengthen the communication between doctors and patients. Depression is expected to vary throughout the life course, as ageing is a risk factor for the development of depression and depressive symptoms. In this study, the distribution of age-related depression had two peaks and varied in different groups. Outpatients aged 30--40 years old had a similar depression prevalence as outpatients aged 80--90 years old, with rates ranging between 30.0% and 40.0%. However, previous research on the association between age and depression has shown contradictory patterns.[@R38] Klerman noted a particular emergence of childhood depression and an increase in suicide attempts and death among adolescents and young adults.[@R39] Outpatients aged 30--40 years suffering from chronic medical illnesses are at higher risk for developing depression. Depressed outpatients might develop maladaptive rumination and illness perception towards their chronic medical illness.[@R41] Chronic medical illness may increase the risk of suicide in adult outpatients because psychosomatic complaint such as headache was found to be an important risk factor for suicide in adults.[@R42] Yang showed that depression declined with age.[@R40] By contrast, Jorm revealed that there was no consistent pattern across studies regarding age differences in the occurrence of anxiety, depression or distress.[@R38] Our results showed that the prevalence of depression and depressive symptoms peaked among individuals aged 30--40 years and 80--90 years, consistent with the U-shaped ageing trajectory of depression reported by a previous study.[@R43] It has been suggested that depression reaches its highest level in elderly aged 80 years or older because physical dysfunction and low personal control add to personal and status losses.[@R43] Risk factors of geriatric depression include poor health, brain injury, low folate and vitamin B12 and raised plasma homocysteine levels.[@R44] The association between depression and chronic medical illnesses in elderly is due to accompanying poor self-reported health and functional status.[@R45] Further, history of depression and antidepressant treatment are important risk factors for elderly suicide.[@R46] The prevalence of depression and depressive symptoms was found to be higher (p\<0.0001) in developing countries (24.0%) than in developed countries (33.0%), a greater difference and much higher than the 12-month prevalence estimates in developed (5.5%) and developing countries (5.9%) found in Kessler\'s study.[@R47] However, a possible limitation of this finding is that Kessler\'s study was restricted to a small number of countries, a narrower range of severe patients and a shorter research time.[@R47] More specifically, 13 studies from China were included in the present meta-analysis. The prevalence of depression or depressive symptoms among Chinese outpatients was 27.0% (1941/7194, 95% CI 22.0% to 33.0%, I^2^=95.4%), which fell between the prevalence observed in developing and developed countries (24.0%--33.0%) and consistent with China's national development.

Various factors may account for the heterogeneity in this meta-analysis. First, differences in the assessments instruments and cut-offs may have affected the diagnostic sensitivity and specificity. Modified diagnostic criteria for depression and depressive symptoms have been proposed for use in different health settings, but there is no consensus regarding the optimal diagnostic approach. Whether the existing diagnostic criteria are ideal in different health settings remains to be determined. Additionally, little attention has been devoted to the ICD (International Classification of Diseases) criteria, in which a depressive episode is defined based on the number and severity of the symptoms only.[@R48] Second, heterogeneity between individual studies existed due to the different diagnostic methods applied in different countries. Third, the study qualities varied. For example, some studies used screening instruments with non-standard methods (eg, with cut-off scores that have not been validated) or having different thresholds in depression measurements that may increase the errors of prevalence estimates. These variations were captured in part by the modified Newcastle-Ottawa score, which assessed the risk of bias in each study.

Publication bias was assessed in this review. First, the exclusion of non-English publications likely contributed to the bias in our analysis. However, given the large number of included studies, we would not expect missed studies to significantly affect the findings. Second, because of the nature of the specialty, some studies examined the rates of depression in females only. For example, the prevalence of depression in obstetrics and gynaecology departments was 25.0%, which may have caused selection bias. Also, the ageing of the population phenomenon may have a more profound impact of depression estimates in developed counties comparing with developing countries. Third, the estimates of prevalence in some specialties were based on an inadequate number of studies, which may have affected the accuracy of the overall depression prevalence. For instance, the prevalence of depression in otorhinolaryngology departments was 53.0%, which was calculated using data from only three studies. Third, studies with fewer participants generally yielded more extreme prevalence estimates, further suggesting the presence of publication bias.[@R49] The study quality is also an important factor for evaluating the presence of publication bias. However, the sensitivity analysis showed that no individual study affected the overall prevalence estimate.

Limitations of this meta-analysis {#s4a}
---------------------------------

Limitations should be considered when interpreting the results of this study. First, the substantial heterogeneity between studies was not fully explained by the variables examined. For example, various disease categories, the onset of depressive episode, medical expenses, medical workers' attitudes and patients' race and gender may contribute to the risk of depressive symptoms among outpatients. Furthermore, compared with self-report scales, interview methods commonly underestimate the prevalence of psychiatric disorders.[@R5] Second, the major update from the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) to the fifth edition in 2013 may have affected the accuracy of the prevalence estimates.[@R50] The severity indicator for depression and depressive symptoms was updated to be more precise, and this change may explain the increase in prevalence between 2010 and 2016. Third, the data were collected from studies that used different cross-sectional study designs, including different diseases and sample sizes. For example, in otorhinolaryngology departments, only three diseases were included in the meta-analysis, leading to low representativeness; however, given the available publications in the database, we would not expect this limitation to significantly affect the findings. Another limitation is the paucity of longitudinal data, which decreased the generalisability of the study outcomes. Therefore, high-quality studies that use cohort study designs to conduct follow-ups of depression might provide more precise outcomes.[@R52] Fourth, using a single measure to assess depression and depressive symptom might improve the accuracy and sensitivity of the outcomes. Finally, focusing on depression alone is insufficient. Depression and depressive symptoms with other mental disorders remain an important and overlooked complication among outpatients, and this oversight calls for a more systematic approach to clinical assessment and follow-up. In conclusion, this systematic review and meta-analysis highlighted the overall high prevalence of depression and depressive symptoms, which may have long been overlooked in outpatients worldwide. Our study also provided substantial quantitative subgroup analyses that laid the foundation for researchers, clinicians and policy makers to develop effective strategies for depression management.

Conclusion {#s5}
==========

In summary, our study has several implications for clinical practice. First, we performed a systematic review and meta-analysis to estimate the prevalence of depression and depressive symptoms in different clinical departments. Second, our results suggest that more attention should be devoted to outpatient mental health, particularly in clinical departments with a high depression prevalence (eg, outpatients at otolaryngology clinics had the highest prevalence of depression (53.0%)). The inconsistency of the findings across different specialties regarding the prevalence of outpatients with depression could help modify and improve clinical guidelines for the evaluation and diagnosis of depression or depressive symptoms in different medical settings. Third, we identified that different screening instruments produce different estimates, and these findings may provide a reliable reference for developing an effective and unified measurement for diagnosing depression. Fourth, the substantial heterogeneity between studies was not fully explained by the variables examined.
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